Clinical Trial Update: Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration [Phase 4]

View source ↗

Summary

This is a Phase 4 clinical trial evaluating fixed monthly dosing of ranibizumab for neovascular age-related macular degeneration. The study reports efficacy res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Wet Macular Degeneration | Phase 4 | Status: COMPLETED